Trial Information
Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer
Inclusion Criteria:
- Provision of informed consent
- Postmenopausal, hormon receptor positive patients with early breast cancer treated
with Arimidex
- Investigators are requested to recruit patients only with at least 1 month prior
Arimidex treatment.
Exclusion Criteria:
- Allergy to substance of medication
- Pre-perimenopausal woman
- Woman not eligible for treatment
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Elements of the investigator questionnaire SF RAND-36 questionnaire
Outcome Time Frame:
Quarterly (plus or minus 3 days )
Safety Issue:
No
Principal Investigator
Zsolt Horváth, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
National Institute of Oncology
Authority:
Hungary: National Institute of Pharmacy
Study ID:
NIS-OHU-ARI-2007/1
NCT ID:
NCT00692289
Start Date:
June 2008
Completion Date:
July 2010
Related Keywords:
- Breast Cancer
- Quality of Life
- Breast Neoplasms